NCT01369017View on ClinicalTrials.gov

Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy Control Subjects
Interventions
DRUG

Anakinra

Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.

DRUG

Placebo

Injection of NS

Trial Locations (1)

27599

UNC Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Michelle Hernandez, MD

OTHER

NCT01369017 - Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers | Biotech Hunter | Biotech Hunter